Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. - Wikidata - awgldk - TriplyDB

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

http://www.wikidata.org/entity/Q37626783

about

Development of Novel Immunotherapies for Multiple Myeloma Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.A panel of circulating miRNAs as diagnostic biomarkers for screening multiple myeloma: a systematic review and meta-analysis.Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.Diagnosis of chronic lymphoproliferative disorders by flow cytometry using four-color combinations for immunophenotyping: A proposal of the Brazilian Group of Flow Cytometry (GBCFLUX).The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients.Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.CARs in the Lead Against Multiple Myeloma.Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.Standardisation of minimal residual disease in multiple myeloma.Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas.CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.

P2860

Q28066890-65B79506-052E-408C-A5FB-05D4431EC7E3 Q30938779-8DA520A9-9A72-42A6-85D3-23D4CA0DC29D Q34802461-79F58F7E-AF41-4479-B54B-0E577D9CC3D2 Q36199559-DE5EBABB-95B5-4BCB-BD9F-BE1A8C41942F Q36284584-CA50384A-0CF4-4B0F-A07B-B82A46E4F3E0 Q36705534-B3094EC4-78DF-4BDD-917B-F9CC211805E7 Q37641783-68B64AC4-A7D7-4FD2-8031-726AD4EF8C8C Q38256196-F8BF83AB-712A-4001-AD03-B158E52E54D8 Q38679490-173426C4-789F-4239-963D-B3AE05110A18 Q38881884-D489EA5A-8B6C-4983-808C-AA03FC53CFE3 Q38922393-6797F51E-46EF-4DEF-A980-51793FC91A75 Q39050210-C7E82C8A-05A9-4719-B430-27A739EC32B7 Q39148797-F5278612-2DCC-4D87-B27B-575FA29FD4DD Q39336938-76FB3462-90CB-4956-AD1C-16DB7EED5093 Q39410899-D520F055-1EBC-46A4-9C48-B3A10484CD3D Q40109575-8B79CF4A-1FE1-4F3B-93A7-64B72A42135C Q41557109-EEA75552-3048-4D89-A6A9-6D99DB73F3A9 Q42983340-A36030E0-50FB-47D0-BE40-C9EEAFDE5DF8 Q47125786-A4DEE2C3-0F77-492B-8D5B-ACAF03E2E250 Q48958626-15704CB5-10B1-4F62-8860-C28D80C85B98 Q51035100-189B0B5C-47EC-4978-8BD8-4F61D04A8B34 Q51804210-AA37704B-155F-43EC-8256-5AB65099EA12 Q52579654-F9052E2F-D9DD-46A1-8C3B-4B802F6BB743 Q54979818-6230F9B9-BD56-44DC-9B1F-E13D8FF86A5C

P2860

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

http://www.wikidata.org/entity/Q37626783

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Flow cytometric differentiatio ...... ma and its precursor diseases.

@en

Flow cytometric differentiatio ...... ma and its precursor diseases.

@nl

type

label

Flow cytometric differentiatio ...... ma and its precursor diseases.

@en

Flow cytometric differentiatio ...... ma and its precursor diseases.

@nl

prefLabel

Flow cytometric differentiatio ...... ma and its precursor diseases.

@en

Flow cytometric differentiatio ...... ma and its precursor diseases.

@nl

P1433

Q37626783-9673BA0C-491C-4E52-9E6B-DEE2C629900B

P1476

Q37626783-D2AE36F2-F459-4092-8991-60BCEB1C3973

P2093

Q37626783-02DA6ECF-7B7E-4211-B034-B727F98AF0B5

Q37626783-2026BA56-6B58-4F3D-8861-59CABA994408

Q37626783-402CC09E-0B46-4064-A883-6562DA685F05

Q37626783-405CDD85-9AC1-4CEE-B7E2-C5005A60C165

Q37626783-4CA45A65-3E61-4E6E-9FCD-C07686B3BF87

Q37626783-5337C64A-D846-453F-9E90-D7F9A9FC2D2A

Q37626783-8C076792-BCDC-4D45-8072-7AFA0756F476

Q37626783-91769C50-2F85-4028-9241-00A5392C8F2D

Q37626783-A1A1DCD8-B0E1-4B52-83B4-26EC094E0A68

Q37626783-A302BA5F-63CA-4259-9530-C41E0D8CA0EB

P2860

Q37626783-0B6369AF-EA43-4563-B114-86AE0D5B538E

Q37626783-0C0E54AC-7D53-41B5-8281-98DEF0643168

Q37626783-101CAD2B-0C89-4CC1-AD7A-0CA39AD0B03A

Q37626783-31EDB07C-A17D-4C27-81FE-16D5C53E7E59

Q37626783-3CE7DA46-5610-4408-8D58-6E512EA27319

Q37626783-4BE830DE-8C2D-4593-96F1-6657CFD7354A

Q37626783-4D246D5B-F07F-4C22-B492-CE60926B42A5

Q37626783-4F4B3E77-E326-4D64-BE48-3C6F2891F95F

Q37626783-5575E5E3-EDBA-4C55-8F4C-A94EA7CF4AC6

Q37626783-590998D0-E2A7-43F2-A759-ED673785E489

P304

Q37626783-ECFD2347-E7BE-4AE0-80A5-95F1F6949551

P31

Q37626783-E4B9B19B-F091-4767-9613-6799F15F8042

P356

Q37626783-DA26CF37-8B4B-43D1-BCDB-97DB8E989B10

P433

Q37626783-A289189B-1BC3-4379-AD97-43E8120A1116

P478

Q37626783-E6B1712E-367D-4B25-B812-3F1FFF2A6A4F

P50

Q37626783-710EF50B-6E4F-4FC5-A791-5D8DFA27115D

P577

Q37626783-C7940791-6DB9-4A4C-A96E-348EAEA7E09D

P5875

Q37626783-B0D0F0AA-37BA-4C5B-9535-6C7C2956C14F

P698

Q37626783-9F6A91F8-4DDB-4B8C-90EB-27E81D122BEE

P921

Q37626783-907F9044-4EAA-47BC-903D-9568687A2EF7

Q37626783-BE050716-1E80-45AE-AB9A-226CED90AF19

P932

Q37626783-20F3B692-41DE-4E46-BED3-9AB88BC823DB

P356

J.LEUKRES.2013.12.007

P1433

Leukemia Research

P1476

Flow cytometric differentiatio ...... ma and its precursor diseases.

@en

P2093

Constance M Yuan

http://www.w3.org/2001/XMLSchema#string

David Liewehr

http://www.w3.org/2001/XMLSchema#string

David Venzon

http://www.w3.org/2001/XMLSchema#string

Diamond Zuchlinsky

http://www.w3.org/2001/XMLSchema#string

Elisabet Manasanch

http://www.w3.org/2001/XMLSchema#string

Irina Maric

http://www.w3.org/2001/XMLSchema#string

Katherine Calvo

http://www.w3.org/2001/XMLSchema#string

Manisha Bhutani

http://www.w3.org/2001/XMLSchema#string

Marcia Mulquin

http://www.w3.org/2001/XMLSchema#string

Mark Roschewski

http://www.w3.org/2001/XMLSchema#string

P2860

Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

CD45: a critical regulator of signaling thresholds in immune cells.

Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system.

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.

P304

371-376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LEUKRES.2013.12.007

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259509290

http://www.w3.org/2001/XMLSchema#string

P698

24462038

http://www.w3.org/2001/XMLSchema#string

P921

P932

3947595

http://www.w3.org/2001/XMLSchema#string